GeneDx, Futu Face Securities Lawsuits
Analysis based on 88 articles · First reported May 19, 2026 · Last updated Jul 04, 2026
The market is negatively impacted by the class action lawsuits against Nubank and Nubank. Nubank' stock price fell significantly due to reported financial results and an impairment charge related to Fabric Genomics, while Nubank' stock declined due to regulatory penalties from the China — China Securities Regulatory Commission. These events create uncertainty and potential financial losses for investors in both companies.
Multiple law firms, including The Schall Law Firm, Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Rosen Law Firm, Kahn Swick & Foti, Hagens Berman, Bleichmar Fonti & Auld LLP, and Faruqi & Faruqi, have filed or are investigating class action lawsuits against Nubank and Nubank. Nubank is accused of making false and misleading statements regarding its acquisition of Fabric Genomics and its Q1 2026 financial results, which included a significant impairment charge and lowered earnings projections, causing a 49.20% stock drop. Nubank is facing allegations of operating securities, public fund sales, and futures businesses in mainland China without the necessary licenses from the China — China Securities Regulatory Commission, leading to proposed penalties of approximately RMB1.85 billion (USD271 million) and a 27.5% stock decline. Investors in both companies are encouraged to join these lawsuits before the respective lead plaintiff deadlines.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard